Home > Publications database > Editorial: Immunotherapy for NSCLC with oncogenic driver variants. > print

001     186487
005     20240229145748.0
024 7 _ |a 10.3389/fonc.2022.1095947
|2 doi
024 7 _ |a pmid:36568249
|2 pmid
024 7 _ |a pmc:PMC9775290
|2 pmc
037 _ _ |a DKFZ-2022-03208
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Du, Yijia
|b 0
245 _ _ |a Editorial: Immunotherapy for NSCLC with oncogenic driver variants.
260 _ _ |a Lausanne
|c 2022
|b Frontiers Media
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1672316690_31235
|2 PUB:(DE-HGF)
|x Editorial
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
536 _ _ |a 316 - Infektionen, Entzündung und Krebs (POF4-316)
|0 G:(DE-HGF)POF4-316
|c POF4-316
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a immune checkpoint inhibitors
|2 Other
650 _ 7 |a lung cancer
|2 Other
650 _ 7 |a oncogenic driver variants
|2 Other
650 _ 7 |a targeted therapy resistance
|2 Other
650 _ 7 |a tumor immune microenvironment
|2 Other
700 1 _ |a Chu, Qian
|b 1
700 1 _ |a Lou, Yanyan
|b 2
700 1 _ |a He, Yong
|b 3
700 1 _ |a Hu, Hongbo
|b 4
700 1 _ |a Hu, Qipeng
|0 P:(DE-He78)37890b29d23d511bbcc2a2fdf82ebe8d
|b 5
|u dkfz
700 1 _ |a Huang, Meijuan
|b 6
773 _ _ |a 10.3389/fonc.2022.1095947
|g Vol. 12, p. 1095947
|0 PERI:(DE-600)2649216-7
|p 1095947
|t Frontiers in oncology
|v 12
|y 2022
|x 2234-943X
909 C O |o oai:inrepo02.dkfz.de:186487
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)37890b29d23d511bbcc2a2fdf82ebe8d
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-316
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Infektionen, Entzündung und Krebs
|x 0
914 1 _ |y 2022
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b FRONT ONCOL : 2021
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-05-11T13:25:45Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-05-11T13:25:45Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-05-11T13:25:45Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-05-11T13:25:45Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-08
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2022-11-08
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b FRONT ONCOL : 2021
|d 2022-11-08
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2022-11-08
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2022-11-08
920 1 _ |0 I:(DE-He78)F100-20160331
|k F100
|l F100 Pathologie infektionsbedingter Tumoren
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)F100-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21